Log in

NASDAQ:AKER - Akers Biosciences Stock Price, Forecast & News

$3.11
-0.07 (-2.20 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$3.08
Now: $3.11
$3.25
50-Day Range
$2.90
MA: $3.30
$3.61
52-Week Range
$2.67
Now: $3.11
$30.24
Volume112,569 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AKER
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees13
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.


Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How were Akers Biosciences' earnings last quarter?

Akers Biosciences Inc (NASDAQ:AKER) issued its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter. View Akers Biosciences' Earnings History.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Akers Biosciences.

Has Akers Biosciences been receiving favorable news coverage?

Media headlines about AKER stock have trended negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akers Biosciences earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Akers Biosciences.

Are investors shorting Akers Biosciences?

Akers Biosciences saw a decline in short interest in January. As of January 31st, there was short interest totalling 12,400 shares, a decline of 73.3% from the January 15th total of 46,400 shares. Based on an average daily volume of 134,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.6% of the company's shares are sold short. View Akers Biosciences' Current Options Chain.

What other stocks do shareholders of Akers Biosciences own?

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the folowing people:
  • Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)

Who are Akers Biosciences' major shareholders?

Akers Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (3.09%). View Institutional Ownership Trends for Akers Biosciences.

Which institutional investors are selling Akers Biosciences stock?

AKER stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Akers Biosciences.

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $3.11.


MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel